SunRock is a biopharmaceutical company, developing sophisticated therapeutic antibodies under innovative formats antibodies to treat incurable cancer. SunRock, working under an open innovation system, aims to develop the different programs from early discovery to the completion of phase I clinical trials. SunRock has developed an extensive portfolio of bispecific molecules targeting CCR9 and HER3 raising high expectation among the key players of the industry.